Peripheral nervous system disease called Guillain-Barre syndrome. During the projection period, 2021-2026, the Guillain-Barre Syndrome Market Study is expected to expand at a CAGR of 4.9%. The COVID-19 virus has a substantial effect on the market for Guillain-Barre syndrome (GBS) treatments.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
